512 주식 개요 투자 지주 회사인 그랜드 제약 그룹은 의약품 및 의료기기, 생명공학 및 헬스케어 제품, 제약 원료의 연구 개발, 제조 및 판매에 종사하는 기업입니다. 자세한 내용
보상 위험 분석 위험 검사에서 512 에 대한 위험이 감지되지 않았습니다.
모든 위험 점검 보기 생각, 링크 및 회사 내러티브를 캡처하세요.
Grand Pharmaceutical Group Limited 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Grand Pharmaceutical Group 과거 주가 현재 주가 HK$4.74 52주 최고치 HK$5.62 52주 최저치 HK$3.17 베타 0.75 1개월 변경 6.52% 3개월 변경 사항 9.47% 1년 변경 사항 22.80% 3년 변화 -26.96% 5년 변화 11.79% IPO 이후 변화 -20.07%
최근 뉴스 및 업데이트
Grand Pharmaceutical Group Limited Submits New Drug Application for the Global Innovative Product GPN01768 to the National Medical Products Administration of the People's Republic of China Dec 16
Grand Pharmaceutical Group Limited's Global Innovative Intravascular Dual-Mode Imaging System NovasyNC Receives Registration Certificate for Medical Device by National Medical Products Administration of the People's Republic of China Dec 12
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA Oct 22
National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11 Oct 14
Investor sentiment improves as stock rises 15% Oct 02 더 많은 업데이트 보기
Grand Pharmaceutical Group Limited Submits New Drug Application for the Global Innovative Product GPN01768 to the National Medical Products Administration of the People's Republic of China Dec 16
Grand Pharmaceutical Group Limited's Global Innovative Intravascular Dual-Mode Imaging System NovasyNC Receives Registration Certificate for Medical Device by National Medical Products Administration of the People's Republic of China Dec 12
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA Oct 22
National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11 Oct 14
Investor sentiment improves as stock rises 15% Oct 02
First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023) Sep 28
Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director Aug 27
First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023) Aug 22
Grand Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024 Aug 15
Grand Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 19, 2024 Aug 09
Grand Pharmaceutical Group Limited Announces Executive Changes Jun 24
Executive Chairman recently bought HK$526k worth of stock Jun 21
Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment Jun 13
Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023 Jun 05
Upcoming dividend of HK$0.26 per share May 30
Executive Chairman recently bought HK$271k worth of stock May 25
Executive Chairman recently bought HK$489k worth of stock May 11 Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024 Apr 28
Executive Chairman recently bought HK$371k worth of stock Apr 21
Executive Chairman recently bought HK$243k worth of stock Apr 06
Executive Chairman recently bought HK$381k worth of stock Mar 22
Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024 Mar 21
Full year 2023 earnings released: EPS: HK$0.54 (vs HK$0.59 in FY 2022) Mar 21
Grand Pharmaceutical Group Limited Proposes Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024 Mar 21
Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024 Mar 08
Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884 Mar 07
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA Dec 27
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002) Nov 03
Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing Oct 25
Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint Sep 14
Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently Aug 18
First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022) Aug 12
Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate Aug 04
Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023 Aug 01
Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China Jul 18
Less than half of directors are independent Jul 12
Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director Jul 01
Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director Jun 22
Less than half of directors are independent Jun 08 Grand Pharmaceutical Group Limited Announces Board Changes
Upcoming dividend of HK$0.14 per share at 2.9% yield Jun 02 Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray
Full year 2022 earnings released: EPS: HK$0.59 (vs HK$0.68 in FY 2021) Mar 23 National Medical Products Administration of the People's Republic of China Accepts Grand Pharmaceutical Group Limited's Investigational New Drug Applications of the Group Three Innovative Products in China
Investor sentiment improved over the past week Dec 29
Grand Pharmaceutical Group Limited Conducts Clinical Trials of its Innovative Oral Small Molecule 3Cl Protease Inhibitor GS221 Against COVID-19 Dec 29
Less than half of directors are independent Nov 16
Investor sentiment improved over the past week Nov 07
Grand Pharmaceutical Group Limited Announces NMPA Approves Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX591-CDx Oct 18
Grand Pharmaceutical Group Limited Announces Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Approved by NMPA Sep 29
First half 2022 earnings released Aug 11
Grand Pharmaceutical Group Limited Provides Unaudited Earnings Guidance for Six Months Ended 30 June 2022 Aug 06
Grand Pharmaceutical Group Announces Clinical Trial Applications in China for Global Innovative Radionuclide-Drug Conjugates TLX591-CDX AND TLX250-CDX Accepted by NMPA Aug 02
Grand Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 10, 2022 Jul 30
Executive Director recently bought HK$535k worth of stock Jun 10
Upcoming dividend of HK$0.11 per share May 30
Grand Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2021 May 28
Full year 2021 earnings released: EPS: HK$0.68 (vs HK$0.52 in FY 2020) Apr 28
Less than half of directors are independent Apr 27
Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial of Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment in China Apr 08
Less than half of directors are independent Mar 22
Sirtex Medical and Grand Pharmaceutical Group Limited Receive NDA Approval of SIR-Spheres® Y-90 Resin Microspheres in China from the National Medical Products Administration Feb 10
First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020) Sep 25
First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020) Aug 12
China Grand Pharmaceutical and Healthcare Holdings Limited (SEHK:512) agreed to acquire 22.2% interest in CoRISMA MCS Systems, Inc for $12 million. Aug 08
Executive Deputy Chairman Bo Hu has left the company Jun 09
Executive Chairman Chengwei Liu has left the company Jun 09
China Grand Pharmaceutical and Healthcare Holdings Limited Announces TLX591-CDx Dosed the First Patient in Japan Jun 03
China Grand Pharmaceutical and Healthcare Holdings Limited Declares Final Dividend for the Year Ended December 31, 2020 At the Annual General Meeting Held on June 1, 2021 Jun 02
Upcoming dividend of HK$0.11 per share Jun 01
China Grand Pharmaceutical and Healthcare Holdings Limited to Introduce the New Generation Heartlight X3 Laser Ablation Platform of Heartlight Endoscopic Ablation System May 31
Investor sentiment improved over the past week May 28
China Grand Pharmaceutical and Healthcare Holdings Limited (SEHK:512) entered into an agreement to acquire Jiangsu Shenming Medical Technology Co., Ltd. for CNY 22.6 million. May 27
Full year 2020 earnings released: EPS HK$0.52 (vs HK$0.35 in FY 2019) May 02
China Grand Pharmaceutical and Healthcare Holdings Limited Announces Declaration of Final Dividend for the Year Ended December 31, 2020 Apr 30
China Grand Pharmaceutical and Healthcare Holdings Limited Recommends Final Dividend for the Year Ended December 31 2020, Payable on or About 23 June 2021 Mar 19
China Grand Pharmaceutical and Healthcare Holdings Limited, Annual General Meeting, Jun 01, 2021 Mar 18
Full year 2020 earnings released Mar 18
New 90-day low: HK$6.06 Mar 09
China Grand Pharmaceutical and Healthcare Holdings Limited to Report Fiscal Year 2020 Results on Mar 17, 2021 Mar 06
China Grand Pharmaceutical and Healthcare Holdings Limited Announces First Patient Dosed in the Phase 1B Clinical Trial for Sepsis of the Group First-In-Class Drug Stc3141 Mar 05
China Grand Pharmaceutical and Healthcare Holdings Limited Receives Drug Registration Certificate for Bimatoprost Eye Drops Mar 04
China Grand Pharmaceutical and Healthcare Holdings Limited (SEHK:512) signed a share purchase agreement to acquire East Ocean Medical (Hong Kong) Company Limited for $12 million. Feb 09
New 90-day high: HK$7.18 Jan 21
China Grand Pharmaceutical and Healthcare Holdings Limited Enters into Cooperative Framework Agreement on Radiation Safety and Environmental Protection with Nuclear and Radiation Safety Center of the Ministry of Ecology and Environment of the PRC Nov 27
Sirtex Medical Inc. and China Grand Pharmaceutical Announce Sir-Spheres® Y-90 Resin Microspheres Nov 26
Telix Pharmaceuticals Limited and China Grand Pharmaceutical and Healthcare Holdings Limited Announces Strategic Licence and Commercial Partnership for Greater China Market Nov 05
New 90-day low: HK$6.41 Oct 28
First half earnings released Sep 18
China Grand Pharmaceutical and Healthcare Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 1.0148 billion. Aug 11
First half earnings released Aug 11
China Grand Pharmaceutical and Healthcare Holdings Limited to Report Q2, 2020 Results on Aug 10, 2020 Aug 09
New 90-day high - HK$6.78 Jul 30 주주 수익률 512 HK Pharmaceuticals HK 마켓 7D 1.3% -1.9% -0.5% 1Y 22.8% -3.9% 19.9%
전체 주주 수익률 보기
수익률 대 산업: 512 지난 1년 동안 -3.9 %를 반환한 Hong Kong Pharmaceuticals 산업을 초과했습니다.
수익률 대 시장: 512 지난 1년 동안 19.9 %를 반환한 Hong Kong 시장을 초과했습니다.
가격 변동성 Is 512's price volatile compared to industry and market? 512 volatility 512 Average Weekly Movement 5.6% Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
안정적인 주가: 512 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: 512 의 주간 변동성 ( 6% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 투자 지주 회사인 그랜드 제약 그룹은 의약품 및 의료기기, 생명공학 및 헬스케어 제품, 제약 원료의 연구 개발, 제조 및 판매에 종사하고 있습니다. 호흡기, 안과, 뇌-심혈관 응급 및 생명공학 관련 제품을 제공합니다. 제약, 타우린, 농약, 화학 의약품 및 아미노산 계열 제품을 제조 및 판매합니다.
자세히 보기 Grand Pharmaceutical Group Limited 기본 사항 요약 Grand Pharmaceutical Group 의 수익과 매출은 시가총액과 어떻게 비교하나요? 512 기본 통계 시가총액 HK$16.60b 수익(TTM ) HK$2.41b 수익(TTM ) HK$10.59b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 512 손익 계산서(TTM ) 수익 HK$10.59b 수익 비용 HK$4.34b 총 이익 HK$6.25b 기타 비용 HK$3.84b 수익 HK$2.41b
주당 순이익(EPS) 0.69 총 마진 59.00% 순이익 마진 22.75% 부채/자본 비율 28.1%
512 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기 기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/21 19:13 장 마감 주가 2024/12/20 00:00 수익 2024/06/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Grand Pharmaceutical Group Limited 7 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Yanyin Zhu China International Capital Corporation Limited Xiao Wei Lin Everbright Securities Co. Ltd. Yiling Chen Guosen Securities Co., Ltd.
4 더 많은 분석가 보기 
